Ruth Lessard
4 Papers
27 Citations
Ruth Lessard is an academic researcher. The author has contributed to research in topics: Factor IX & Medicine. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
Catherine S. Manno,Glenn F. Pierce,Valder R. Arruda,Bertil Glader,Margaret V. Ragni,Rasko Jj,Margareth C. Ozelo,Keith Hoots,Blatt P,Barbara A. Konkle,Michael D. Dake,Robin D. Kaye,Mahmood K. Razavi,A Zajko,James L. Zehnder,Pradip Rustagi,Hiroyuki Nakai,A Chew,Debra G.B. Leonard,Debra G.B. Leonard,J F Wright,Ruth Lessard,Jurg M. Sommer,Michael Tigges,Denise E. Sabatino,A Luk,Haiyan Jiang,Federico Mingozzi,Linda B. Couto,Hildegund C.J. Ertl,Katherine A. High,Katherine A. High,Mark A. Kay +32 more
TL;DR: In this article, a single portal vein infusion of a recombinant adeno-associated viral vector (rAAV) expressing canine Factor IX (F.IX) resulted in long-term expression of therapeutic levels of F.IX in dogs with severe hemophilia B.
2.1K
Human Immune Responses to AAV-2 Capsid May Limit Duration of Expression in Liver-Directed Gene Transfer in Humans with Hemophilia B.
Katherine A. High,Katherine A. High,Katherine A. High,Michael Tigges,Catherine S. Manno,Catherine S. Manno,Denise E. Sabatino,Valder R. Arruda,Valder R. Arruda,Roland W. Herzog,Roland W. Herzog,Pradip Rustagi,John E.J. Rasko,Jurg M. Sommer,Kristen Jaworski,Margaret V. Ragni,Bertil Glader,Ruth Lessard,Alvin Luk,Linda B. Couto,Haiyan Jiang,Glenn F. Pierce,Mark A. Kay +22 more
TL;DR: Data from a Phase I dose escalation study of AAV-FIX in humans with severe hemophilia B are consistent with a model in which a T cell response to AAV capsid epitopes results in elimination of the transduced cells.
15
Correction: Corrigendum: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
Catherine S. Manno,Valder R. Arruda,Glenn F. Pierce,Bertil Glader,Margaret V. Ragni,John E.J. Rasko,Margareth C. Ozelo,Keith Hoots,Blatt P,Barbara A. Konkle,Mike Dake,Robin D. Kaye,Mahmood K. Razavi,A Zajko,James L. Zehnder,Hiroyuki Nakai,A Chew,Debra G.B. Leonard,Debra G.B. Leonard,J F Wright,J F Wright,Ruth Lessard,Jurg M. Sommer,Michael Tigges,Denise E. Sabatino,A Luk,Haiyan Jiang,Federico Mingozzi,Linda B. Couto,Hildegund C. J. Ertl,Hildegund C. J. Ertl,Katherine A. High,Katherine A. High,Mark A. Kay +33 more
TL;DR: In the version of this article originally published, Pradip Rustagi was inadvertently omitted from the author list and John Rasko should be listed as John E. J. Raskso.
1002. Immune Responses to AAV and to Factor IX in a Phase I Study of AAV-Mediated, Liver-Directed Gene Transfer for Hemophilia B
Katherine A. High,Catherine S. Manno,Denise E. Sabatino,Sylvia Hutchison,Michael D. Dake,Mahmood K. Razavi,Robin D. Kaye,Valder Aruda,Roland W. Herzog,Pradip Rustagi,John E.J. Rasko,Keith Hoots,Phillip Blatt,Jurg M. Sommer,Margaret V. Ragni,Margareth C. Ozelo,Barbara A. Konkle,Ruth Lessard,Alvin Luk,Bertil Glader,Glenn F. Pierce,Linda B. Couto,Mark A. Kay +22 more
TL;DR: It is concluded that AAV-F.IX can transduce human hepatocytes in vivo, resulting in therapeutic circulating factor levels and the vector dose required to achieve a therapeutic factor level was accurately predicted by animal models.